French biotechnology company Transgene (Euronext Paris:TNG) and ProBioGen, a contract development and manufacturing organisation (CDMO) in biologics, vaccines and viral vectors, announced on Tuesday that they have joined forces to accelerate the development of personalised cancer vaccines.
Through a licence agreement, ProBioGen's high-yielding AGE1.CR.pIX cell line will be integrated into Transgene's myvac platform for large-scale production.
This collaboration leverages ProBioGen's established bioprocessing technology with Transgene's expertise in individualised cancer immunotherapy. The partnership aims to streamline manufacturing processes, ensuring consistent and cost-effective production of patient-specific cancer treatments.
hVIVO completes pilot study for hMPV challenge model
Merck's Gardasil approved for males in China
Brii Bio acquires BRII-179 IP rights
Valneva and Serum Institute of India partner to expand chikungunya vaccine access in Asia
SK bioscience begins clinical trials for mRNA Japanese encephalitis vaccine
Sanofi's combination vaccine candidates for flu and COVID-19 get Fast Track Designation
hVIVO secures GBP11.5m RSV contract
Novavax sells Czech manufacturing site to Novo Nordisk for USD200m
Valneva reports strong, long-lasting immunity from single-dose chikungunya vaccine